Treatment of breast and brain cancer cells with [MMF + ruxolitinib] for 12h resulted in tumor cell killing; treatment of these tumor cells with [MMF + ruxolitinib] together with either Temozolomide, paclitaxel or with HDAC inhibitors further enhanced the lethality of the initial two drug combination. Here, HDAC9 is linked to brain cancer.